- Home
- WATT vs BTAI Comparison
WATT vs BTAI Comparison
Compare WATT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- BTAI
- Stock Information
- Founded
- WATT 2012
- BTAI 2017
- Country
- WATT United States
- BTAI United States
- Employees
- WATT N/A
- BTAI N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- BTAI Health Care
- Exchange
- WATT Nasdaq
- BTAI Nasdaq
- Market Cap
- WATT 9.3M
- BTAI 8.3M
- IPO Year
- WATT 2014
- BTAI 2018
- Fundamental
- Price
- WATT $0.29
- BTAI $3.32
- Analyst Decision
- WATT
- BTAI Buy
- Analyst Count
- WATT 0
- BTAI 5
- Target Price
- WATT N/A
- BTAI $34.80
- AVG Volume (30 Days)
- WATT 2.5M
- BTAI 14.2M
- Earning Date
- WATT 07-29-2025
- BTAI 08-15-2025
- Dividend Yield
- WATT N/A
- BTAI N/A
- EPS Growth
- WATT N/A
- BTAI N/A
- EPS
- WATT N/A
- BTAI N/A
- Revenue
- WATT $1,976,000.00
- BTAI $1,852,000.00
- Revenue This Year
- WATT $1,028.91
- BTAI N/A
- Revenue Next Year
- WATT N/A
- BTAI $328.13
- P/E Ratio
- WATT N/A
- BTAI N/A
- Revenue Growth
- WATT 434.05
- BTAI 5.47
- 52 Week Low
- WATT $0.12
- BTAI $1.17
- 52 Week High
- WATT $2.70
- BTAI $16.64
- Technical
- Relative Strength Index (RSI)
- WATT 37.22
- BTAI 78.01
- Support Level
- WATT $0.35
- BTAI $1.30
- Resistance Level
- WATT $0.61
- BTAI $1.83
- Average True Range (ATR)
- WATT 0.07
- BTAI 0.37
- MACD
- WATT -0.02
- BTAI 0.15
- Stochastic Oscillator
- WATT 0.09
- BTAI 94.37
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.